Alerta

COMPOSITIONS AND ARTICLES COMPRISING (NANO)DIAMOND PARTICLES

Resumen de: US20260183419A1

0000 Compositions and articles comprising diamond particles, such as nanodiamond based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).

FREEZE-DRYING PROTECTIVE AGENT FOR NUCLEIC ACID-LIPID NANOPARTICLES, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Resumen de: US20260183381A1

Based on the physicochemical principles of the freeze-drying process, the present invention performs systematic research on the freeze-drying conditions of nucleic acid-lipid nanoparticles, namely a freeze-drying process and a freeze-drying protective agent, optimizing and designing an efficient freeze-drying method suitable for the nucleic acid-lipid nanoparticles. According to the invention, the total duration of the nucleic acid-lipid nanoparticle freeze-drying process can be reduced to 8-18 hours, significantly reducing the energy consumption and the time cost of scaled-up product production; the freeze-dried nucleic acid-lipid nanoparticles rehydrate rapidly (within 10 seconds), and have a high total nucleic acid content, encapsulation efficiency and nucleic acid integrity; moreover, the cell transfection efficiency of a freeze-dried rehydrated preparation is not significantly different from that of a nucleic acid-lipid nanoparticle stock solution which has not been freeze-dried, and the in-vivo immune response is high and even exceeds that of a nucleic acid-lipid nanoparticle stock solution which has not been freeze-dried.

SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN

Resumen de: US20260184764A1

0000 The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

GENE DELIVERY NANOPARTICLE, AND PREPARATION AND APPLICATION THEREOF

Resumen de: US20260183247A1

The present disclosure provides a gene delivery nanoparticle, and its preparation and application, pertaining to the technical field of biomedicine. In the preparation method, 2-((tert-butoxycarbonyl)amino)ethyl methacrylate as monomer, mPEG5k-RAFT as macromolecular chain transfer agent and azobisisobutyronitrile as initiator are subjected to reversible addition-fragmentation chain transfer polymerization in dimethylformamide, dialysis and freeze-drying to obtain an intermediate; the intermediate is dissolved in dichloromethane, added with trifluoroacetic acid and reacted to yield polyethylene glycol-poly(aminoethyl methacrylate); sparfloxacin is dissolved in a hydrochloric acid solution, and added with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and a solution of polyethylene glycol-poly(aminoethyl methacrylate) in dimethyl sulfoxide to produce a mixture; the mixture is subjected to dialysis and freeze-drying to obtain the final product polyethylene glycol-poly(sparfloxacin), which is placed in an aqueous solution to allow self-assembly, thereby forming the desired nanoparticle.

CANNABIS COMPOSITIONS, ORAL PRODUCTS, AND METHODS OF MAKING SAME

Resumen de: AU2024390078A1

The disclosed technology includes cannabinoid oral products, and methods for making same. In some embodiments, the oral products are pouches including cannabinoid infused wafers. In some embodiments, the method of making the cannabinoid oral products includes preparing an emulsion, preparing a spray dry solution, spray drying solution into cannabinoid and carbohydrate particles, preparing a paste, preparing a wafer in a heated vacuum oven, fragmenting the wafer into cannabinoid infused wafer fragments, mixing the cannabinoid infused wafer fragments with starch, and dispensing the cannabinoid infused wafer fragments into pouches. The methods may also include labeling the oral products, for example, with a THC warning symbol.

CAI NANOEMULSIONS

Resumen de: US20260183267A1

The present disclosure relates to nanoemulsions of 5-amino-4-(4-chlorobenzoyl)-3,5-dichlorobenzyl-1,2,3-triazole-4-carboxamide (carboxy-amido-triazole or CAI), methods of preparing thereof, and their use in the treatment of inflammatory optic neuropathies.

COMPOSITIONS AND METHODS FOR MODULATING CXCL9, CXCL10, AND CXCL11 GENE EXPRESSION

Resumen de: US20260183426A1

The present invention provides agents and compositions for reducing expression of a CXCL9, CXCL10, and/or CXCL11 gene by targeting expression control region associated with CXCL9, CXCL10, and/or CXCL11 gene and methods of use thereof for treating a disease or disorder associated with CXCL9, CXCL10, and/or CXCL11, e.g., liver disease.

NANOEMULSION WITHOUT PROPYLENE GLYCOL

Resumen de: US20260183237A1

0000 The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.

TARGETING VEHICLES, COMPOSITIONS AND USES THEREOF

Resumen de: US20260183416A1

0000 A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.

OXYGEN CARRIER PHARMACEUTICAL COMPOSITION CONTAINING PERFLUOROCARBON AND CASEIN, AND PREPARATION METHOD THEREFOR

Resumen de: AU2024412664A1

The present invention provides a pharmaceutical composition in which perfluorocarbon is formulated in the form of a nanoemulsion using casein or a salt thereof, and a preparation method therefor. In the pharmaceutical composition of the present invention, perfluorocarbon may be present in the form of stable liquid particles in the nanoemulsion. Therefore, the pharmaceutical composition of the present invention can avoid side effects such as thrombus formation or vascular occlusion, and thus can be useful as an artificial oxygen carrier, i.e., a blood substitute.

NOVEL COMPOSITIONS AND USES

Resumen de: AU2023475155A1

The present disclosure is concerned with compositions comprising monodisperse assemblies of allene oxide synthase (AOS), and in particular compositions and assembles comprising AOS enzymes and polysorbate surfactants. Such compositions have improved enzymatic activity that are particularly useful for remediating biological conditions of oxidative stress.

ACTIVATED NANOTHERAPY FOR SICKLE CELL DISEASE

Resumen de: US20260183420A1

We disclose here the nano-enabled delivery of highly potent 5-hydroxymethyl furfural (5-HMF) to sickled blood cells in patients. 5-HMF, a superior antisickling agent, has been formulated to address the limitations of existing treatment modalities arising from disfavorable pharmacokinetics of the drug compound. Specifically, two complementary 5-HMF prodrugs are integrated as a ‘protected’ biocompatible composite nanoparticle designed to readily fuse with RBCs and be amenable to transdermal delivery (5-HMF-grafted-phospholipid layered over a sucrose-derived graphitic carbon dot core). These RBC-targeted, protected, biocompatible, self-assembled 5-HMF prodrug nanoparticles for sickle cell disease are the first in class technology for offering a treatment for sickle cell disease which has improved potency, targeted payload delivery, and extended release with the red blood cells with enhanced pharmacodynamic effect in a treated patient.

Inhibitory Nucleic Acids and Methods of Use Thereof

Resumen de: US20260183329A1

The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various disorders.

CRISPR-Cas Effector Polypeptides, Lipid Nanoparticles, and Methods of Use Thereof

Resumen de: US20260185070A1

0000 The present disclosure provides variant CRISPR-Cas effector polypeptides, nucleic acids encoding same, and compositions comprising the variant CRISPR-Cas effector polypeptides. The present disclosure provides methods of modifying a target nucleic acid, using a variant CRISPR-Cas effector polypeptide of the present disclosure. The present disclosure provides lipid nanoparticles comprising a CRISPR-Cas effector polypeptide and a guide nucleic acid.

LIPID COMPOUND AND COMPOSITION FOR DELIVERY OF ACTIVE SUBSTANCE

Resumen de: US20260184669A1

Disclosed are a new lipid compound and a new lipid nanoparticle (LNP) composition comprising the lipid compound. The lipid compound according to the present disclosure may enhance the structural stability of an active substance by directly or indirectly binding to the active substance through multivalent interactions to encapsulate the active substance. In addition, the lipid nanoparticle composition comprising the lipid compound may significantly improve the intracellular delivery efficiency and activity of the active substance, therefore may be useful for the treatment and prevention of the disease.

LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERING POLYNUCLEOTIDES

Resumen de: US20260184668A1

0000 Described herein are novel lipids that can be used in combination with other lipid components, such as helper lipids, structural lipids, and cholesterols, to form lipid nanoparticles for delivery of therapeutic agents, such as nucleic acids (e.g., circular polynucleotides), both in vitro and in vivo.

COMPOSITION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE NEUROLOGICAL DISORDER, COMPRISING PLGA-SISTAT3 AS ACTIVE INGREDIENT

Resumen de: US20260183327A1

0000 The present invention relates to a composition for prevention or treatment of autoimmune neurological disorder, comprising nanoparticles (PLGA-siSTAT3) comprising STAT3-specific siRNA and a biodegradable polymer material, the present invention having confirmed that, in an EAE animal model, which is a multiple sclerosis or encephalomyelitis animal model, the PLGA-siSTAT3 reduces a clinical symptom index induced by EAE, and inhibits demyelination of the spinal cord. In addition, the present invention has been confirmed to block a STAT3 signaling pathway associated with EAE and thus reduce demyelination, and inhibit microglial and neuroglial expression. In addition, the present invention has been confirmed to inhibit the inflammatory factors iNOS, IL-1β, IL-6, TNF-α, and inhibit the expression of the inflammation-mediating enzyme COX-2 and the chemokines MIP-1α, RANTES. In addition, the present invention has been confirmed to inhibit the invasion and activity of Th1 and Th17 cells associated with autoimmunity and thus enable reducing autoimmune neurological disorder.

NOVEL METHODS FOR LYOPHILIZED KEFIR-LOADED SELF-NANOEMULSIFYING DELIVERY SYSTEM OF CARAWAY OIL AND LICORICE EXTRACT ON COGNITIVE FUNCTION VIA THE MICROBIOTA-GUT-BRAIN AXIS

Resumen de: US20260183352A1

Chronic inflammatory bowel disorders (IBDs) are characterized by altered intestinal permeability, prompting inflammatory, oxidative stress and immunological factors. Gut microbiota disorders impact brain function via the bidirectional gut-brain axis, influencing behavior through inflammatory cascades, oxidative stress, and neurotransmitter levels. The present invention comprises lyophilized milk kefir alone and lyophilized milk kefir as solid carriers loaded with self-nanoemulsifying self-nanosuspension (SNESNS) of licorice extract. Daily administration of lyophilized milk kefir loaded with SNESNS restores normal body weight and intestinal mucosa while significantly reducing submucosal inflammatory cell infiltration, leading to significant alleviation of neurotransmitter levels and improved memory functions, thereby addressing gut-brain axis disorders. Additionally, it normalized fecal microbiome constituents, inflammatory cytokine levels, and oxidative stress in examined tissues and serum. Moreover, daily administration of kefir-loaded SNESNS normalizes the disease activity index, alleviates histopathological changes induced by IBD induction, and partially restored the normal gut microbiota. These alterations are associated with improved cognitive functions, attributed to the maintenance of normal neurotransmitter levels and alleviation of triggered inflammatory factors and oxidative stress levels.

SHIELDING CATALYTIC BIOMATERIAL AND IMAGE GUIDANCE DELIVERY PLATFORM

Resumen de: WO2026142744A2

Compositions and methods are presented to improve the efficacy and reduce the side-effects of radiological cancer treatments. Nanoparticles of cerium oxide are dispersed within a biodegradable polymer matrix to form a biomaterial that can be implanted in a patient at a selected location and remain at that location for a period of time encompassing all or part of a radiation therapy course of treatment. Among other functions of the implanted biomaterial, it may act as a spacer such that organs at risk are moved away from tissues targeted by the radiation therapy. Another function of the implanted biomaterial is as a fiducial marker. The use of cerium oxide will assist in achieving both the fiducial marker and spacer functions, particularly in view of the catalytic activity of cerium oxide in reducing a number of reactive oxygen species to non-reactive compounds The composition may permit higher doses of radiation and improved survival rates resulting therefrom.

PHARMACEUTICAL SYSTEM

Resumen de: WO2026142951A1

Provided are lipid-based systems, compositions, and methods of making and using the same. The lipid-based systems contain lipid nanoparticles and specifically formulated liposomes to reduce or prevent lipid nanoparticle clearance in vivo in subjects towards LNPs or components thereof.

PHARMACEUTICAL COMPOSITION COMPRISING TLR4 AND TLR7 AGONISTS

Resumen de: WO2026139138A1

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-Iike receptor 7 (TLR7) agonist and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition, a kit or kit of parts and the medical use of the pharmaceutical composition and the kit or kit of parts.

LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2026142992A1

Provided herein are lipid nanoparticles (LNPs) comprising an ionizable or cationic lipid, a helper lipid, a structural lipid, and a stealth lipid. The LNPs provided herein can be useful for delivery and expression of mRNA and encoded protein and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

PHARMACEUTICAL COMPOSITION FOR MEDICAL USE COMPRISING TLR4 AND TLR7 AGONISTS

Resumen de: WO2026139139A1

The present invention provides a pharmaceutical composition comprising solid particles comprising at least one toll-like receptor 4 (TLR4) agonist and micelles comprising at least one toll-like receptor 7 (TLR7) agonistfor use as a medicament or for use in the treatment of cancer, an antibiotic resistance, an inflammatory condition or disease, an autoimmune disease or an infectious disease and at least one amphiphilic micelle-forming agent. Also provided is a method of preparing the pharmaceutical composition and a kit or kit of parts comprising the pharmaceutical composition for use.

POLYGLYCEROL CONJUGATED LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS

Resumen de: WO2026139004A1

Provided herein are polyglycerol conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes. Also provided herein are lipid nanoparticle compositions comprising said polymer conjugated lipid compounds.

LIPID, LIPID NANOPARTICLE INCLUDING THE SAME AND USE OF LIPID NANOPARTICLE

Nº publicación: WO2026143214A1 02/07/2026

Solicitante:

DEV CENTER FOR BIOTECHNOLOGY
DCB USA LLC [US]
DCB-USA LLC
DEVELOPMENT CENTER FOR BIOTECHNOLOGY

Resumen de: WO2026143214A1

A lipid is represented by Formula (I), wherein each of the substituents in Formula (I) is given the definition as set forth in the Specification and Claims. A lipid nanoparticle including the lipid, a helper lipid, a steroid, a PEGylated lipid, a branched-chain ionizable cationic lipidoid with five hydroxyl groups, and a nucleic acid is also provided. A method for delivering a nucleic acid to a subject using a pharmaceutical composition including the lipid nanoparticle, and a pharmaceutical composition for delivering a nucleic acid to a subject are also provided.